File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Increasing prevalence of hypertension and central obesity in the Hong Kong cardiovascular risk factor prevalence study

TitleIncreasing prevalence of hypertension and central obesity in the Hong Kong cardiovascular risk factor prevalence study
Authors
KeywordsPharmacy and pharmacology environmental studies
Toxicology and environmental safety
Issue Date2011
PublisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/PTO
Citation
The 10th Congress of the European Association for Clinical Pharmacology and Therapeutics, Budapest, Hungary, 26-29 June 2011. In Basic & Clinical Pharmacology & Toxicology, 2011, v. 109 suppl. s1, p. 108, abstract no. P164 How to Cite?
AbstractINTRODUCTION: Hypertension is known to be related to obesity. We studied the prevalence of hypertension over a period of 11.9 years in the population-based Hong Kong Cardiovascular Risk Factor Prevalence Study (CRISPS) cohort and investigated its association with changes in body mass index (BMI) and waist circumference. METHODS: A total of 2888, 1942 and 1798 subjects in CRISPS-1 (1995–1996), CRISPS-2 (2000–2004) and CRISPS-3 (2005–2008), respectively, were included in this analysis. Hypertension was defined as blood pressure ‡140/90 mmHg or taking anti-hypertensive medication. General obesity was defined as BMI ‡27.5 kg/m2 and central obesity was defined as waist circumference ‡90 cm in men or ‡80 cm in women. RESULTS: The prevalence of hypertension increased from 18.1% to 39.4% (P < 0.001 after adjusting for age and sex). The prevalence of central obesity increased from 25.4% to 41.4%, but that of general obesity decreased from 16.8% to 14.8% (both P < 0.001 after adjusting for age and sex). Among 1347 subjects who did not take any anti-hypertensive medication at both CRISPS-1 and CRISPS-3, the change in waist circumference, but not that in BMI, was associated with the changes in both systolic and diastolic blood pressures (beta = 0.087, P = 0.015 and beta = 0.122, P < 0.001 respectively). CONCLUSIONS: An increase in the prevalence of hypertension was observed in the cohort, which might be explained by the increase in central rather than general obesity. Our findings further confirm the importance of measuring the waist circumference, as opposed to just calculating the BMI, in this population.
DescriptionThis journal suppl. is Special Issue: Abstracts of the 10th Congress of the European Association for Clinical Pharmacology and Therapeutics
Posters
Persistent Identifierhttp://hdl.handle.net/10722/137758
ISSN
2015 Impact Factor: 3.097
2015 SCImago Journal Rankings: 0.539

 

DC FieldValueLanguage
dc.contributor.authorCheung, BMYen_US
dc.contributor.authorOng, KLen_US
dc.contributor.authorTso, AWKen_US
dc.contributor.authorLam, THen_US
dc.contributor.authorLam, KSLen_US
dc.date.accessioned2011-08-26T14:33:01Z-
dc.date.available2011-08-26T14:33:01Z-
dc.date.issued2011en_US
dc.identifier.citationThe 10th Congress of the European Association for Clinical Pharmacology and Therapeutics, Budapest, Hungary, 26-29 June 2011. In Basic & Clinical Pharmacology & Toxicology, 2011, v. 109 suppl. s1, p. 108, abstract no. P164en_US
dc.identifier.issn1742-7835-
dc.identifier.urihttp://hdl.handle.net/10722/137758-
dc.descriptionThis journal suppl. is Special Issue: Abstracts of the 10th Congress of the European Association for Clinical Pharmacology and Therapeutics-
dc.descriptionPosters-
dc.description.abstractINTRODUCTION: Hypertension is known to be related to obesity. We studied the prevalence of hypertension over a period of 11.9 years in the population-based Hong Kong Cardiovascular Risk Factor Prevalence Study (CRISPS) cohort and investigated its association with changes in body mass index (BMI) and waist circumference. METHODS: A total of 2888, 1942 and 1798 subjects in CRISPS-1 (1995–1996), CRISPS-2 (2000–2004) and CRISPS-3 (2005–2008), respectively, were included in this analysis. Hypertension was defined as blood pressure ‡140/90 mmHg or taking anti-hypertensive medication. General obesity was defined as BMI ‡27.5 kg/m2 and central obesity was defined as waist circumference ‡90 cm in men or ‡80 cm in women. RESULTS: The prevalence of hypertension increased from 18.1% to 39.4% (P < 0.001 after adjusting for age and sex). The prevalence of central obesity increased from 25.4% to 41.4%, but that of general obesity decreased from 16.8% to 14.8% (both P < 0.001 after adjusting for age and sex). Among 1347 subjects who did not take any anti-hypertensive medication at both CRISPS-1 and CRISPS-3, the change in waist circumference, but not that in BMI, was associated with the changes in both systolic and diastolic blood pressures (beta = 0.087, P = 0.015 and beta = 0.122, P < 0.001 respectively). CONCLUSIONS: An increase in the prevalence of hypertension was observed in the cohort, which might be explained by the increase in central rather than general obesity. Our findings further confirm the importance of measuring the waist circumference, as opposed to just calculating the BMI, in this population.-
dc.languageengen_US
dc.publisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/PTO-
dc.relation.ispartofBasic & Clinical Pharmacology & Toxicologyen_US
dc.rightsThe definitive version is available at www.blackwell-synergy.com-
dc.subjectPharmacy and pharmacology environmental studies-
dc.subjectToxicology and environmental safety-
dc.titleIncreasing prevalence of hypertension and central obesity in the Hong Kong cardiovascular risk factor prevalence studyen_US
dc.typeConference_Paperen_US
dc.identifier.emailCheung, BMY: mycheung@hku.hken_US
dc.identifier.emailOng, KL: okl2000@hku.hken_US
dc.identifier.emailTso, AWK: awktso@hku.hken_US
dc.identifier.emailLam, TH: hrmrlth@hkucc.hku.hken_US
dc.identifier.emailLam, KSL: ksllam@hku.hken_US
dc.identifier.authorityCheung, BMY=rp01321en_US
dc.identifier.authorityTso, AWK=rp00535en_US
dc.identifier.authorityLam, TH=rp00326en_US
dc.identifier.authorityLam, KSL=rp00343en_US
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1111/j.1742-7843.2011.00722.x-
dc.identifier.hkuros189573en_US
dc.identifier.volume109en_US
dc.identifier.issuesuppl. s1en_US
dc.identifier.spage108en_US
dc.identifier.epage108en_US
dc.publisher.placeUnited Kingdom-
dc.description.otherThe 10th Congress of the European Association for Clinical Pharmacology and Therapeutics, Budapest, Hungary, 26-29 June 2011. In Basic & Clinical Pharmacology & Toxicology, 2011, v. 109 suppl. s1, p. 108, abstract no. P164-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats